Nasus Pharma Announces Upcoming Presentation at H.C. Wainwright 27th Annual Global Investment Conference

Rhea-AI Summary

Nasus Pharma (NYSE:NSRX), a clinical-stage pharmaceutical company specializing in intranasal emergency medical treatments, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. The virtual presentation will be delivered by CEO Dan Teleman on September 5, 2025, from 7:00-7:30 AM ET.

The company will also be available for one-on-one meetings with investors during the conference, which can be arranged through H.C. Wainwright representatives.

News Market Reaction – NSRX

-0.74%

2 alerts

-0.74% Session close to close

$78.50M Market Cap

0.0x Rel. Volume

In the Sep 2 session, NSRX declined 0.74%, reflecting a mild negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

TEL AVIV, Israel, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced that company management will present at the H.C. Wainwright 27th Annual Global Investment Conference.

• Location: Virtual
• Date: September 5, 2025
• Time: 07:00-07:30 a.m. ET
• Type: Company presentation        
• Presenter: Dan Teleman, Chief Executive Officer
• Webcast: Registration Link

Nasus management will be available for one-on-one meetings during the conference. Interested investors should contact their respective representative at the sponsoring institutions to request meetings.

About Nasus Pharma

Nasus Pharma is a clinical-stage pharmaceutical company developing a number of intranasal powder products addressing acute medical conditions in the community. NS002, Nasus’s intranasal powder Epinephrine product candidate is being developed as a needle-free alternative to Epinephrine autoinjectors for patients with anaphylaxis. Intranasal administration is most suitable for those situations in which rapid drug delivery is required and offers needle free, easy to use alternatives. Nasus proprietary powder-based intranasal (“PBI”) technology is designed for rapid and reliable drug delivery, leveraging the nasal cavity’s rich vascular network for quick absorption. The PBI formulation uses uniform spherical powder particles for broad dispersion and potentially faster, higher absorption compared to liquid-based nasal products.

Contact
info@nasuspharma.com
Nasus Pharma Ltd. Israel
https://www.nasuspharma.com

Investor Contact
Mike Moyer
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com

FAQ

When is Nasus Pharma (NSRX) presenting at the H.C. Wainwright Conference?

Nasus Pharma is presenting on September 5, 2025, from 7:00-7:30 AM ET at the virtual conference.

Who will be presenting for Nasus Pharma at the H.C. Wainwright Conference?

Dan Teleman, the Chief Executive Officer of Nasus Pharma, will be delivering the company presentation.

How can investors attend Nasus Pharma's presentation at the H.C. Wainwright Conference?

Investors can attend the presentation virtually by registering through the provided webcast registration link.

How can investors schedule one-on-one meetings with Nasus Pharma management?

Investors interested in one-on-one meetings should contact their H.C. Wainwright representatives to request meetings during the conference.